Motilal Oswal Alternates has acquired a majority stake in Megafine Pharma with an investment of ₹460 crore. The deal strengthens Megafine's global API business, backed by its USFDA-approved facilities. The company aims to expand R&D and manufacturing, with a focus on niche, high-value APIs for chronic therapies.